Alzheimer disease and associated disorders
Clinical drug trials in Alzheimer disease. What are some of the issues?
Abstract
Clinical drug trials in Alzheimer disease are underway in many locations throughout the world. That experience has uncovered a number of unique difficulties. In response, members of the Alzheimer's Association Medical and Scientific Advisory Board organized meetings with experts from the government, academia, private practice and the pharmaceutical industry. The issues are presented here along with some suggestions to facilitate planning and to avoid problems in future drug trials.
Source and rights
Published by Alzheimer disease and associated disorders, 1990. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Published
- 1990
- Applies to
- 🇪🇺 Europe
- Scope
- Regional
- Journal
- Alzheimer disease and associated disorders
- PubMed
- 2264978
- Added to Prognia
- 16 July 2026
More in neurology
- Recommendations for early mobilisation at Swiss Stroke Centres and Stroke Units: a practice guide and discussion paperEuropean Respiratory Society · 2026
- Clinical practice guidelines for the care of patients with a chronic subdural haematoma: multidisciplinary recommendations from presentation to recovery
